KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in BRAF-mutant melanoma

Ferrucci, Pier Francesco ; Di Giacomo, Anna Maria ; Del Vecchio, Michele ; Atkinson, Victoria ; Schmidt, Henrik ; Schachter, Jacob ; Queirolo, Paola ; Long, Georgina V ; Stephens, Rosalie ; Svane, Inge Marie ; Lotem, Michal ; Abu-Amna, Mahmoud ; Gasal, Eduard ; Ghori, Razi ; Diede, Scott J ; Croydon, Elizabeth S ; Ribas, Antoni ; Ascierto, Paolo Antonio

Journal for immunotherapy of cancer, 2020-12, Vol.8 (2), p.e001806 [Periódico revisado por pares]

England: BMJ Publishing Group Ltd

Texto completo disponível